American Oncology Partners of Maryland (Bethesda)
The Center for Cancer & Blood Disorders - Bethesda
Bethesda, MD
Accepting patients
ELEMENT-MDS
Phase 3 Clinical Trial Comparing Luspatercept VS Epoetin Alfa in Patients with Very Low – Intermediate Risk MDS Who Are Not Transfusion Dependent
- Erythroid Maturation Agent (EMA)
- Erythropoiesis-Stimulating Agent (ESA)
- Red Blood Cell Stimulant
- Phase 3
Not currently accepting
IBI188
A Phase 1b Study Evaluating the Safety and Efficacy of IBI188 in Combination With Azacitidine in Subjects With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (MDS)
- Monoclonal Antibody
- Phase 1
Accepting patients
AK117/Placebo with Azacitidine
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
- Monoclonal Antibody
- CD47
- Closed Label (Masked)
- Placebo
- Randomization
- Phase 2
- Phase 1/2
- Has results